Onconetix, Inc. (ONCO) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
ONCO's revenue distribution by segment and geography
By Geography
ONCO Revenue Analysis (2019–2024)
As of February 28, 2026, Onconetix, Inc. (ONCO) generated trailing twelve-month (TTM) revenue of $1.2 million, reflecting significant decline in growth of -25.4% year-over-year. The most recent quarter (Q3 2025) recorded $303,651 in revenue, up 185.1% sequentially.
Looking at the longer-term picture, ONCO's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $2.5 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY), ONCO has underperformed the peer group in terms of revenue growth. Compare ONCO vs BNTX →
Peer Comparison
Compare ONCO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ONCOCurrent | $1M | -25.4% | - | -2238.0% | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $2.5M | +4217.3% | $1.1M | 41.8% | $-56,488,755 | -2238.0% |
| 2023 | $58K | - | $-1,127,165 | -1927.9% | $-36,034,595 | -61634.5% |
| 2022 | $0 | - | $-6,752 | - | $-13,481,240 | - |
| 2021 | $0 | - | $-4,890 | - | $-3,417,334 | - |
| 2020 | $0 | - | $-3,056 | - | $-1,622,069 | - |
| 2019 | $0 | - | $-573 | - | $-880,230 | - |
See ONCO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ONCO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ONCO vs AGIO
See how ONCO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ONCO's revenue growth accelerating or slowing?
ONCO revenue declined -25.4% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $1M. This reverses the prior growth trend.
What is ONCO's long-term revenue growth rate?
Onconetix, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -25.4% is below this long-term average.
How is ONCO's revenue distributed by segment?
ONCO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.